Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Daly

Showing results (341-350 of 397) with videos related to

Pageof 40
Sort By:
Biochemical Pharmacology|November 14, 2002
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomesNamrata Bahadur, Julian B S Leathart, Elaine Mutch, et al.
The Journal of Investigative Dermatology|July 8, 2011
Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort studyShyamal Wahie, Ann K Daly, Heather J Cordell, et al.
Clinical Science (London, England : 1979)|October 2, 2010
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver diseaseRika Iwata, Katharina Baur, Bruno Stieger, et al.
Clinical Pharmacology and Therapeutics|August 13, 2024
PharmVar GeneFocus: CYP4F2Pablo Zubiaur, Cristina Rodríguez-Antona, Erin C Boone, et al.
Journal of Hepatology|March 22, 2017
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factorThomas Jacob Urban, Paola Nicoletti, Naga Chalasani, et al.
Gut|February 24, 2010
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver diseaseP Dongiovanni, L Valenti, R Rametta, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Clinical Pharmacology and Therapeutics|June 10, 2021
PharmVar GeneFocus: CYP2C9Katrin Sangkuhl, Karla Claudio-Campos, Larisa H Cavallari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
Pharmacogenetics and Genomics|September 16, 2009
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective studyAndrea L Jorgensen, Sameh Al-Zubiedi, Jieying Eunice Zhang, et al.
Pageof 40

Showing results (341-350 of 397) with videos related to

Sort By:
Pageof 40
Biochemical Pharmacology|November 14, 2002
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomesNamrata Bahadur, Julian B S Leathart, Elaine Mutch, et al.
The Journal of Investigative Dermatology|July 8, 2011
Clinical and pharmacogenetic influences on response to hydroxychloroquine in discoid lupus erythematosus: a retrospective cohort studyShyamal Wahie, Ann K Daly, Heather J Cordell, et al.
Clinical Science (London, England : 1979)|October 2, 2010
A common polymorphism in the ABCB11 gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver diseaseRika Iwata, Katharina Baur, Bruno Stieger, et al.
Clinical Pharmacology and Therapeutics|August 13, 2024
PharmVar GeneFocus: CYP4F2Pablo Zubiaur, Cristina Rodríguez-Antona, Erin C Boone, et al.
Journal of Hepatology|March 22, 2017
Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factorThomas Jacob Urban, Paola Nicoletti, Naga Chalasani, et al.
Gut|February 24, 2010
Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver diseaseP Dongiovanni, L Valenti, R Rametta, et al.
Hepatology (Baltimore, Md.)|June 9, 2021
Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver FibrosisKazuhiro Kozumi, Takahiro Kodama, Hiroki Murai, et al.
Clinical Pharmacology and Therapeutics|June 10, 2021
PharmVar GeneFocus: CYP2C9Katrin Sangkuhl, Karla Claudio-Campos, Larisa H Cavallari, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 16, 2025
Insulin-like Growth Factor-1 Reflects Liver Disease Stage and Improves Prediction of Liver-related MortalityCarolin V Schneider, Stefan Gross, Sriram Balasubramani, et al.
Pharmacogenetics and Genomics|September 16, 2009
Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective studyAndrea L Jorgensen, Sameh Al-Zubiedi, Jieying Eunice Zhang, et al.
Pageof 40